<DOC>
	<DOCNO>NCT00005971</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness flavopiridol treat patient metastatic malignant melanoma .</brief_summary>
	<brief_title>Flavopiridol Treating Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess efficacy flavopiridol patient previously untreated metastatic malignant melanoma . - Assess toxicity treatment patient . - Assess time progression , early progression rate , response duration patient treat regimen . OUTLINE : This multicenter study . Patients receive flavopiridol IV 1 hour day 1-3 . Treatment continue every 21 day maximum 6 course absence disease progression unacceptable toxicity . Patients follow 4 week , every 3 month disease progression death . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic malignant melanoma amenable standard curative therapy No prior regional systemic therapy metastatic disease Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan Bone lesion consider measurable No known CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST great 2.5 time ULN Renal : Creatinine great ULN Cardiovascular : If history cardiac disease , ejection fraction great 50 % No clinically significant cardiac symptomology Pulmonary : If history pulmonary disease , FEV1 , FVC , TLC great 60 % predict DLCO great 50 % predict No clinically significant pulmonary symptomology Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior adjuvant immunotherapy allow No prior immunotherapy metastatic disease Chemotherapy : No prior chemotherapy metastatic disease No concurrent chemotherapy Endocrine therapy : At least 4 week since prior adjuvant hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy recover Must measurable disease outside irradiated area OR Evidence progression new lesion irradiate area No 25 % function bone marrow irradiate No concurrent radiotherapy sole site measurable disease Surgery : At least 4 week since prior major surgery Other : No concurrent anticancer therapy investigational anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage IV melanoma</keyword>
</DOC>